Learn More
INTRODUCTION Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion sub-protocol to the TEAM (Tamoxifen and Exemestane Adjuvant Multicenter) International trial, we compared the effect of the(More)
Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease. In this study, a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial, we compared the effect of the steroidal aromatase(More)
BACKGROUND The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting. PATIENTS AND METHODS Lipidemic profile changes were studied in 142 postmenopausal patients randomized to(More)
BACKGROUND Locally advanced breast cancer (LABC) remains a major clinical issue despite progress achieved in recent years. Herein, we present the mature results of a multimodality treatment program tailoring epirubicin (EPI), docetaxel (DOC) and gemcitabine-vinorelbine (GEV) peri-operatively in LABC. PATIENTS AND METHODS Stage III, Eastern Cooperative(More)
552 Background: The management of bone mineral density (BMD) in postmenopausal, breast cancer (BC) patients (pts) receiveing anastrozole was investigated in this phase III, multicenter, open label trial. METHODS Pretreatment BMD of 217 eligible pts with hormone receptor-positive BC scheduled to receive anastrozole was evaluated at lumbar spine (LS) and(More)
INTRODUCTION The aim of this observational study was to assess the combined impact of chemotherapy (CT) and aromatase inhibitors (AI) therapy on bone mineral density (BMD) in postmenopausal women with estrogen receptor (ER)-positive early breast cancer. METHODS Patients were treated with a third generation AI, either as adjuvant therapy (HT cohort, n =(More)
799 Background: Side effects of endocrine therapy for breast cancer (BC) may have clinical implications. Drugs that alter lipid profile potentially interfere with the risk of developing cardiovascular disease (CVD). Tamoxifen (T) has proven to have a favorable effect on CVD risk factors by modestly decreasing total plasma cholesterol (TC) and low-density(More)
AIMS The objective of this retrospective study was to describe the results from five institutions' experience of using Oncotype DX(®) to identify patients who need chemotherapy despite the presence of primarily favorable characteristics. PATIENTS AND METHODS Oncotype DX was performed in 106 pre- and postmenopausal patients with estrogen receptor-positive,(More)
  • 1